Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 8935 results

  1. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development Reference number: GID-TA10553 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Awaiting development Reference number: GID-TA10694 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development Reference number: GID-TA11040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]

    Awaiting development Reference number: GID-TA11673 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Bimekizumab for treating ankylosing spondylitis [ID4011]

    Awaiting development Reference number: GID-TA11150 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pridopidine for treating Huntington's disease [ID6525]

    Awaiting development Reference number: GID-TA11637 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]

    Awaiting development Reference number: GID-TA11814 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development Reference number: GID-TA10990 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  14. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development